WAM
IBB icon

Wakefield Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Wakefield Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,730
Closed -$1.38M – 176
2022
Q2 		$1.38M Buy
+11,730
New +$1.39M 0.59% 61

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wakefield Asset Management's IBB Position: Q3 2022 in Review

Wakefield Asset Management sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 11,730 shares — an estimated $1.38M sold.

Wakefield Asset Management first reported a position in IBB in Q2 2022 and held it in 1 quarter. The position peaked at $1.38M in Q2 2022. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

  • Wakefield Asset Management reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
  • Wakefield Asset Management sold 11,730 iShares Biotechnology ETF shares in Q3 2022, an estimated $1.38M.
  • Wakefield Asset Management first reported a position in iShares Biotechnology ETF in Q2 2022 and held it in 1 quarter.
  • Wakefield Asset Management's iShares Biotechnology ETF position peaked at $1.38M in Q2 2022.
  • 829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Wakefield Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.